Novogenia AG, a Munich-based healthcare company specializing in human genetics and personalized products, has announced its exclusive participation as a technology and manufacturing partner in a planned clinical study under the 10XREVIV initiative in Abu Dhabi, United Arab Emirates. The study, part of a previously announced collaboration involving healthcare partners M42, 10X Health, and REVIV Global, will investigate the potential benefits of personalized dietary supplements for patients receiving GLP-1 therapy. Novogenia will conduct and evaluate DNA analyses and develop and manufacture personalized dietary supplements for study participants based on the results.
The study design initially calls for the enrollment of 500 participants in Abu Dhabi. It aims to determine the extent to which individually tailored nutritional support, alongside standard care, can positively influence participants’ nutritional status, muscle and fat percentages, well-being—particularly quality of life and fatigue levels—and their consistent adherence to treatment. The clinical trial will be conducted by Insights Research Organization and Solutions (IROS), a contract research organization belonging to M42, and 10XREVIV.
“The 10XREVIV initiative is a key component of our international growth strategy,” said Dr. Daniel Wallerstorfer, CEO of Novogenia AG. “Through our participation in the planned study, we are contributing our core competencies in genetic analysis and the manufacture of personalized dietary supplements to a scientific study. The study aims to provide insights into the additional benefits that individually tailored nutritional support can offer to people receiving GLP-1 therapy. We see this as an important avenue for applying our technologies in the international healthcare market.”
The initiative coincides with strong growth in the global market for GLP-1-based therapies, which is expected to rise from approximately $66 billion in 2025 to more than $185 billion by 2033, according to market forecasts. As these therapies become more widely used, ensuring adequate nutrient intake is gaining importance. A U.S. study published in 2025 involving more than 460,000 adults prescribed GLP-1 therapy documented that 22.4% experienced a nutrient deficiency or a related complication for the first time within one year. These findings highlight the importance of adequate nutrient intake during GLP-1 therapy, although other factors may also contribute to the development of nutrient deficiencies.
Novogenia’s involvement in the planned study builds on its previously communicated strategic direction and strengthens its position as a technology and manufacturing partner in personalized healthcare. Preparations for the Middle East include adapting products to regional requirements and obtaining Halal certification. The company’s genetic analyses, conducted in its own laboratory, are used in diagnosis, treatment, and prevention of diseases, as well as in the production of individually tailored nutritional supplements and cosmetics. Novogenia also partners with physicians, therapists, pharmacists, nutritionists, and fitness trainers to provide optimized care based on genetic predispositions.
The original release can be viewed on www.newmediawire.com.
